ADDvise receives order worth USD 2.1 million

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from Cochran Wholesale Pharmaceuticals, a generic pharmaceutical wholesale distributor serving the needs of independent pharmacies across the USA. The order is worth approximately USD 2.1 million. The order regards delivery of Folite, a folic acid dietary supplemental developed and manufactured by Poly Pharmaceuticals. Delivery will take place immediately.  
 

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on December 16, 2022, at 07:15 CET.
 

About ADDvise Group
 

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.